Pharmaceuticals

Positive Dupixent Phase 3 results in adults and adolescents with eosinophilic esophagitis 

Positive Dupixent Phase 3 results in adults and adolescents

1 Comment / Pharmaceuticals /

Positive Dupixent Phase 3 results in adults and adolescents with eosinophilic esophagitis  The New England Journal of Medicine has published results from a positive Phase 3 trial showing adults and adolescents treated with Dupixent® (dupilumab) 300 mg weekly experienced significant improvements in signs and symptoms of eosinophilic esophagitis (EoE), which were sustained for up to one year.  EoE is […]

Positive Dupixent Phase 3 results in adults and adolescents Read More »

Roivant & Pfizer Form New Vant Company to Develop TL1A Drug Candidate

Roivant & Pfizer Form New Vant Company

Pharmaceuticals /

Roivant & Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases  Roivant Sciences and Pfizer Inc.has announced formation of a new Vant to develop and commercialize PF-06480605 (now RVT-3101). RVT-3101 is a fully human monoclonal antibody targeting TL1A, which is currently in Phase 2b development in ulcerative colitis (UC).

Roivant & Pfizer Form New Vant Company Read More »

Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data

1 Comment / Pharmaceuticals /

Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age Pfizer Inc.  and BioNTech SE has announced updated efficacy results from a Phase 2/3 trial evaluating a three 3-µg dose series of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months through 4 years of age, reinforcing previously reported

Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Read More »